Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)

Next Previous
Search
Trial Profile

A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ARPEGGIO
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries

Most Recent Events

  • 26 Feb 2022 Results using data from ORATORIO, OLYMPUS and ARPEGGIO; predicting the conditional average treatment effect for individuals taking anti-CD20 monoclonal antibodies and laquinimod by using deep learning, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022
  • 10 Jul 2020 Results published in the Neurology
  • 17 May 2018 According to an Active Biotech media release, data from this study were presented at the Annual Meeting of the American Academy of Neurology (AAN).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top